James Condulis
Stock Analyst at Stifel Nicolaus
(3.84)
# 1,902
Out of 4,575 analysts
45
Total ratings
64.1%
Success rate
12.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Initiated Coverage: Buy | $98 | $85.60 | +14.49% | 1 | Jul 14, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $25 → $3 | $3.72 | -19.35% | 5 | Jun 2, 2026 | |
| EWTX Edgewise Therapeutics | Maintained: Hold | n/a | $40.84 | - | 5 | Jun 1, 2026 | |
| TECX Tectonic Therapeutic | Maintained: Buy | $75 | $30.37 | +146.95% | 2 | May 8, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $130 → $136 | $113.03 | +20.32% | 7 | May 7, 2026 | |
| CYTK Cytokinetics | Rated: Buy | $98 → $108 | $80.74 | +33.76% | 15 | May 6, 2026 | |
| AMLX Amylyx Pharmaceuticals | Initiated Coverage: Buy | $21 | $18.41 | +14.07% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgraded: Hold | $24 → $6 | $6.32 | -5.06% | 4 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Buy | $50 | $29.64 | +68.69% | 4 | Feb 6, 2026 | |
| XFOR X4 Pharmaceuticals | Initiated Coverage: Buy | $10 | $3.85 | +159.74% | 1 | Dec 5, 2025 |
Arrowhead Pharmaceuticals
Jul 14, 2026
Initiated Coverage: Buy
Price Target: $98
Current: $85.60
Upside: +14.49%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $25 → $3
Current: $3.72
Upside: -19.35%
Edgewise Therapeutics
Jun 1, 2026
Maintained: Hold
Price Target: n/a
Current: $40.84
Upside: -
Tectonic Therapeutic
May 8, 2026
Maintained: Buy
Price Target: $75
Current: $30.37
Upside: +146.95%
Mirum Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $130 → $136
Current: $113.03
Upside: +20.32%
Cytokinetics
May 6, 2026
Rated: Buy
Price Target: $98 → $108
Current: $80.74
Upside: +33.76%
Amylyx Pharmaceuticals
Mar 3, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $18.41
Upside: +14.07%
Aardvark Therapeutics
Mar 2, 2026
Downgraded: Hold
Price Target: $24 → $6
Current: $6.32
Upside: -5.06%
NewAmsterdam Pharma Company
Feb 6, 2026
Maintained: Buy
Price Target: $50
Current: $29.64
Upside: +68.69%
X4 Pharmaceuticals
Dec 5, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $3.85
Upside: +159.74%